Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash from Operations (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Cash from Operations for 6 consecutive years, with 10726000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 41.06% year-over-year to 10726000.0, compared with a TTM value of 30651000.0 through Sep 2025, up 50.27%, and an annual FY2024 reading of 28940000.0, up 43.17% over the prior year.
  • Cash from Operations was 10726000.0 for Q3 2025 at Barinthus Biotherapeutics, up from 18109000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 13086000.0 in Q4 2024 and bottomed at 19603000.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 8979789.47, with a median of 11191000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations tumbled 1439.37% in 2021, then skyrocketed 688.9% in 2022.
  • Year by year, Cash from Operations stood at 7972000.0 in 2021, then crashed by 42.29% to 11343000.0 in 2022, then plummeted by 72.82% to 19603000.0 in 2023, then skyrocketed by 166.76% to 13086000.0 in 2024, then crashed by 181.97% to 10726000.0 in 2025.
  • Business Quant data shows Cash from Operations for BRNS at 10726000.0 in Q3 2025, 18109000.0 in Q2 2025, and 14902000.0 in Q1 2025.